San Diego, CA, United States of America

Andrew Charles Vendel

USPTO Granted Patents = 3 

 

 

Average Co-Inventor Count = 3.8

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Cardiff-by-the-Sea, CA (US) (2016)
  • San Diego, CA (US) (2020 - 2022)

Company Filing History:


Years Active: 2016-2022

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Andrew Charles Vendel: Innovator in Autoimmune Disease Treatment

Introduction

Andrew Charles Vendel is a prominent inventor based in San Diego, CA. He has made significant contributions to the field of medicine, particularly in the treatment of autoimmune diseases. With a total of 3 patents to his name, Vendel is recognized for his innovative approaches to healthcare.

Latest Patents

Among his latest patents are the BTLA agonist antibodies and their uses. These antibodies bind to BTLA and are designed to treat conditions associated with autoimmune diseases, including lupus. The development of these antibodies represents a significant advancement in therapeutic options for patients suffering from such conditions.

Career Highlights

Vendel is currently employed at Eli Lilly and Company, where he continues to work on groundbreaking research and development in the pharmaceutical industry. His expertise and dedication have positioned him as a key figure in the advancement of treatments for autoimmune diseases.

Collaborations

Some of his notable coworkers include Shane Krummen Atwell and Victor H Obungu. Their collaborative efforts contribute to the innovative environment at Eli Lilly and Company, fostering advancements in medical research.

Conclusion

Andrew Charles Vendel's work in developing BTLA agonist antibodies showcases his commitment to improving treatment options for autoimmune diseases. His contributions to the field are invaluable and highlight the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…